|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
BCRP mRNA and FLT3-ITD are independent poor risk factors in adult patients with acute myeloid leukemia and intermediate or normal karyotype.
|
28618074 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML.
|
28618016 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
ABCG2 was expressed at higher levels in subtypes of AML with favorable outcome but within standard- and high-risk patients, it was associated with poor outcome (P = 0.02).
|
26512967 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, ABCG2 overexpression at AML diagnosis identifies a subset of patients with poor outcome also after allogeneic SCT, mainly in terms of higher relapse rates.
|
26059733 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
A median fluorescence intensity ratio (MFIR) which measures the efflux of mitoxantrone (an ATP Binding Cassette (ABC) transporter substrate) with and without ABC transporter inhibition correlates with expression of MDR1 and BCRP in acute myeloid leukemia (AML) blasts.
|
26002514 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We have analyzed the expression of MDR-1, multidrug resistant protein-1 (MRP-1), breast cancer resistance protein (BCRP), and lung resistance protein (LRP) messenger RNA (mRNA) in relation to the mutational status of FLT3-ITD and MLL-PTD in 185 acute myeloid leukemia (AML) adult patients.
|
24030729 |
2014 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
ABCG2 protein overexpression and FLT3 internal tandem duplication (ITD) correlate with higher relapse rate and shorter disease-free survival (DFS) in acute myeloid leukemia (AML), but no data are available on the possible effect of concomitant presence of these 2 factors.
|
21523728 |
2011 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We also show a relatively high incidence of ABCG2 mRNA expression in non-Down associated M7 AML, which may contribute to the relatively poor prognosis of the M7 AML subtype.
|
21640380 |
2011 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
Over-expression of multidrug resistance (MDR) proteins PGP and BCRP has a negative prognostic impact in acute myeloid leukemia (AML) patients.
|
20122734 |
2010 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The relative expression of the drug-efflux pumps P-gp, MRP, LRP, and BCRP was evaluated by mean fluorescence index (MFI) and the Kolmogorov-Smirnov analysis (D values) in five leukemic subpopulations: CD34+CD38-CD123+ (LSCs), CD34+CD38+CD123-, CD34+CD38+CD123+, CD34+CD38+CD123-, and CD34- mature cells in 26 bone marrow samples of CD34+ AML cases.
|
18200595 |
2008 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
LHGDN |
The relative expression of the drug-efflux pumps P-gp, MRP, LRP, and BCRP was evaluated by mean fluorescence index (MFI) and the Kolmogorov-Smirnov analysis (D values) in five leukemic subpopulations: CD34+CD38-CD123+ (LSCs), CD34+CD38+CD123-, CD34+CD38+CD123+, CD34+CD38+CD123-, and CD34- mature cells in 26 bone marrow samples of CD34+ AML cases.
|
18200595 |
2008 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Using quantitative reverse transcriptase polymerase chain reaction, we measured expression of the ABC transporter superfamily in the blast cells from AML patients prior to chemotherapy.
|
18249061 |
2008 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
WP744 overcomes transport by Pgp, MRP-1 and BCRP in cell lines and AML cells and is a promising agent for clinical development in AML and other malignancies with broad-spectrum multidrug resistance.
|
17072745 |
2007 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The clinical value of MDR1, MRP1, LRP/MVP, and BCRP messenger RNA (mRNA) expression was prospectively studied in 154 newly diagnosed AML patients >or=60 years who were treated in a multicenter, randomized phase 3 trial.
|
17340137 |
2007 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance.
|
17368038 |
2007 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
P-glycoprotein (PGP) over-expression has an unfavorable prognostic significance, while the role of breast cancer resistance protein (BCRP) is less clear, especially in AML patients with a normal karyotype.
|
16704962 |
2006 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
LHGDN |
BCRP may, therefore, be regarded as a prognostic factor in patients with normal karyotype AML, for the design of risk-adapted post-remission therapy.
|
16704962 |
2006 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
This suggests a possible role of BCRP in drug resistance in AML.
|
15607361 |
2005 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
LHGDN |
BCRP and MRP3 may also be involved in chemoresistance in AML, especially MRP3 in patients with M5 FAB.
|
16278398 |
2005 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
BCRP and MRP3 may also be involved in chemoresistance in AML, especially MRP3 in patients with M5 FAB.
|
16278398 |
2005 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
AlteredExpression
|
disease |
LHGDN |
Presence of BCRP only in subpopulations and discordance among BCRP measurements suggest complex biology of BCRP in AML and incomplete modeling by cell lines.
|
15208643 |
2004 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
BCRP would be implicated in the resistance to chemotherapies in AML.
|
15585622 |
2004 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
Presence of BCRP only in subpopulations and discordance among BCRP measurements suggest complex biology of BCRP in AML and incomplete modeling by cell lines.
|
15208643 |
2004 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
LHGDN |
At diagnosis BCRP activity was undetectable in AML blasts from 23/26 cases, while Pgp activity was present in 36/45 and MRP activity in 26/44 of the cases.
|
12604403 |
2003 |